CN110248661A - 前列腺癌的治疗 - Google Patents

前列腺癌的治疗 Download PDF

Info

Publication number
CN110248661A
CN110248661A CN201780072970.4A CN201780072970A CN110248661A CN 110248661 A CN110248661 A CN 110248661A CN 201780072970 A CN201780072970 A CN 201780072970A CN 110248661 A CN110248661 A CN 110248661A
Authority
CN
China
Prior art keywords
formulation
oral
administration
subject
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780072970.4A
Other languages
English (en)
Chinese (zh)
Inventor
V·R·拉贾塞卡尔
B·M·约翰逊
D·B·麦克莱恩
L·西里
小保罗·N·马德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meng Owen Science Co Ltd
Takeda Pharmaceutical Co Ltd
Original Assignee
Meng Owen Science Co Ltd
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110248661(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meng Owen Science Co Ltd, Takeda Chemical Industries Ltd filed Critical Meng Owen Science Co Ltd
Publication of CN110248661A publication Critical patent/CN110248661A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201780072970.4A 2016-09-30 2017-09-29 前列腺癌的治疗 Pending CN110248661A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662402150P 2016-09-30 2016-09-30
US201662402004P 2016-09-30 2016-09-30
US62/402,150 2016-09-30
US62/402,004 2016-09-30
PCT/EP2017/074849 WO2018060463A2 (en) 2016-09-30 2017-09-29 Treatment of prostate cancer

Publications (1)

Publication Number Publication Date
CN110248661A true CN110248661A (zh) 2019-09-17

Family

ID=60915459

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780072970.4A Pending CN110248661A (zh) 2016-09-30 2017-09-29 前列腺癌的治疗

Country Status (21)

Country Link
US (8) US10449191B2 (https=)
EP (2) EP3518932B1 (https=)
JP (1) JP7062673B2 (https=)
CN (1) CN110248661A (https=)
AU (2) AU2017334035B2 (https=)
BR (1) BR112019006228A2 (https=)
CA (1) CA3038875A1 (https=)
DK (1) DK3518932T3 (https=)
ES (1) ES3002857T3 (https=)
FI (1) FI3518932T3 (https=)
HR (1) HRP20241740T1 (https=)
HU (1) HUE070578T2 (https=)
IL (3) IL308528A (https=)
LT (1) LT3518932T (https=)
MA (1) MA46361A (https=)
MX (2) MX2019003733A (https=)
NZ (1) NZ752918A (https=)
PL (1) PL3518932T3 (https=)
PT (1) PT3518932T (https=)
SI (1) SI3518932T1 (https=)
WO (1) WO2018060463A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115175912A (zh) * 2019-10-10 2022-10-11 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
JP2022551316A (ja) * 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
WO2022087593A1 (en) * 2020-10-20 2022-04-28 Baylor College Of Medicine Multiplex metabolic markers in plasma for early detection of african american prostrate cancer
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2023152611A1 (en) * 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016136849A1 (ja) * 2015-02-26 2016-09-01 武田薬品工業株式会社 固形製剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
KR20030005205A (ko) 2000-02-29 2003-01-17 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 유도체의 제조 방법
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
US7569570B2 (en) 2002-01-30 2009-08-04 Takeda Pharmaceutical Company Limited Thienopyrimidines, process for preparing the same and use thereof
BRPI0307786B8 (pt) 2002-02-26 2021-05-25 Astrazeneca Ab composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
AU2004257639B2 (en) 2003-07-07 2011-01-06 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
EP2155194B1 (en) 2007-04-06 2015-01-21 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
US10821152B2 (en) 2014-08-26 2020-11-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
US9949974B2 (en) 2015-09-01 2018-04-24 Abbvie Inc. Methods of adminstering elagolix
US20180044977A1 (en) 2016-08-12 2018-02-15 Raynor Mfg. Co. Rolling door construction for controlling air leakage
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016136849A1 (ja) * 2015-02-26 2016-09-01 武田薬品工業株式会社 固形製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MACLEAN, D. B.等: "Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males", 《THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM》 *
SHORE, N. D.等: "PD28-01 TESTOSTERONE LOWERING, PSA RESPONSE AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED HORMONE SENSITIVE PROSTATE CANCER RECEIVING TAK-385, AN ORAL GNRH ANTAGONIST: PHASE 2 INTERIM ANALYSIS", 《THE JOURNAL OF UROLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115175912A (zh) * 2019-10-10 2022-10-11 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式

Also Published As

Publication number Publication date
EP3518932B1 (en) 2024-11-13
PL3518932T3 (pl) 2025-04-07
CA3038875A1 (en) 2018-04-05
US10449191B2 (en) 2019-10-22
US20250082632A1 (en) 2025-03-13
EP3518932A2 (en) 2019-08-07
WO2018060463A3 (en) 2018-05-11
US12097198B2 (en) 2024-09-24
JP7062673B2 (ja) 2022-05-06
MX2023001468A (es) 2023-03-03
US20200129507A1 (en) 2020-04-30
IL300071A (en) 2023-03-01
IL265697A (en) 2019-05-30
EP4520398A3 (en) 2025-04-02
US20220401443A1 (en) 2022-12-22
US20250057839A1 (en) 2025-02-20
IL265697B2 (en) 2023-07-01
US20190224196A1 (en) 2019-07-25
MA46361A (fr) 2021-03-31
IL265697B1 (en) 2023-03-01
SI3518932T1 (sl) 2025-03-31
US11583526B2 (en) 2023-02-21
US20210205303A1 (en) 2021-07-08
HUE070578T2 (hu) 2025-06-28
US12336990B2 (en) 2025-06-24
DK3518932T3 (da) 2025-01-27
JP2019529574A (ja) 2019-10-17
AU2023201047B2 (en) 2025-04-03
MX2019003733A (es) 2019-09-26
EP4520398A2 (en) 2025-03-12
BR112019006228A2 (pt) 2019-06-18
IL308528A (en) 2024-01-01
US20240358700A1 (en) 2024-10-31
AU2017334035B2 (en) 2022-11-24
FI3518932T3 (fi) 2025-02-03
AU2023201047A1 (en) 2023-03-23
WO2018060463A2 (en) 2018-04-05
US10786501B2 (en) 2020-09-29
US12144809B1 (en) 2024-11-19
HRP20241740T1 (hr) 2025-02-28
PT3518932T (pt) 2025-01-16
AU2017334035A1 (en) 2019-05-16
LT3518932T (lt) 2025-02-10
US20250332166A1 (en) 2025-10-30
ES3002857T3 (en) 2025-03-07
NZ752918A (en) 2022-09-30

Similar Documents

Publication Publication Date Title
CN110248661A (zh) 前列腺癌的治疗
US11957684B2 (en) Treatment of heavy menstrual bleeding associated with uterine fibroids
CN116096373A (zh) 用于治疗先天性肾上腺增生症的crf1受体拮抗剂
TWI778979B (zh) 治療女性不孕症之方法
HK40116485A (en) Treatment of prostate cancer
EA043716B1 (ru) Лечение рака предстательной железы
HK40012835A (en) Treatment of prostate cancer
HK40012835B (en) Treatment of prostate cancer
US20090062246A1 (en) Therapeutic treatment-014
Wong Abarelix Oncolytic

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190917

WD01 Invention patent application deemed withdrawn after publication